• Tanshinone IIA: Evidence-Bounded Overview

  2026-10-18

  APExBIO describes Tanshinone IIA as a tanshinone compound associated with NF-κB and AP-1 DNA-binding inhibition, cancer-cell cytotoxicity, β-amyloid aggregation inhibition, and protection of PC12 cells from β-amyloid-associated apoptosis. These statements define a plausible research scope, but the cited product information provides no identity-matched study, quantitative outcomes, comparator data, or independent validation. The compound’s documented properties therefore support hypothesis framing rather than conclusions about efficacy, selectivity, or therapeutic use.

• Rosetta(DE3) pLysS: Evidence Boundaries

  2026-10-17

  The available product metadata identifies APExBIO’s Rosetta(DE3) pLysS Competent Cell as SKU BC2011, but it provides no product description or identity-matched research evidence. The term “competent cell” supports only a category-level interpretation involving host-cell uptake of exogenous nucleic acid; the supplied information does not establish the molecular basis of the DE3 or pLysS design, quantitative performance, expression behavior, or suitability in any particular application.

• SUMO Protease (Ulp): Mechanism and Evidence

  2026-10-16

  APExBIO’s K1103 product description presents SUMO Protease (Ulp) as a recombinant yeast-derived Ulp1 cysteine protease for processing compatible SUMO fusion proteins. The documented mechanism and product scope are clear at a conceptual level, but the available material provides no identity-matched research study, quantitative performance data, or direct comparison with alternative tag-removal enzymes.

• DIDS: Product Identity and Mechanistic Scope

  2026-10-16

  DIDS, or 4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid, is listed by APExBIO as an anion transport inhibitor with reported activity across ClC-Ka, bacterial ClC-ec1, calcium-activated chloride currents, TRPV1-associated responses, vascular smooth muscle, hyperthermia-related tumor models, and neonatal ischemia-hypoxia models. Because no identity-matched paper is available, these claims should be treated as vendor-reported evidence rather than as an independently verified literature record. The reported IC50 values are assay-specific and do not establish selectivity, mechanism of action in intact systems, or translational efficacy.

• AS1842856: What the Product Record Supports

  2026-10-15

  AS1842856 is cataloged by APExBIO as a Foxo1 inhibitor with reported effects on Foxo1-mediated transcription, gluconeogenic gene expression, glucose production, and autophagy-related research readouts. Because no identity-matched paper is available, these claims should be treated as supplier-documented observations rather than independently verified evidence, with applicability limited to the described assay and animal contexts.

• SUMO Protease (Ulp): Identity and Evidence Scope

  2026-10-15

  APExBIO describes SKU K1103 as a recombinant yeast Ulp1-derived cysteine protease intended for junction-specific removal of SUMO fusion tags. The supplied information supports a documented product identity and conceptual mechanism, but not independent claims about kinetics, cleavage completeness, recovery, selectivity across constructs, or preservation of protein function.

• SUMO Protease (Ulp): Identity and Evidence Scope

  2026-10-14

  APExBIO’s K1103 is described as a recombinant yeast Ulp1-derived cysteine protease for conceptual removal of compatible SUMO fusion tags. The product information supports a mechanistic interpretation of SUMO-junction cleavage and describes activity across broad pH, temperature, and salt ranges, but no identity-matched peer-reviewed study or independent performance dataset is available to establish specificity, kinetics, recovery, or applicability across target proteins.

• METTL14, SMN and the Evidence for m6A Regulation

  2026-10-14

  A source-grounded overview of how arginine methylation may regulate METTL14–SMN interactions and RNA m6A homeostasis, with attention to evidence strength, disease relevance and study limitations.

• Dhcr7 Disruption and GCRV Resistance in Grass Carp

  2026-10-13

  A 2026 Aquaculture Reports study presents in vivo evidence that dhcr7 disruption is associated with greater resistance to GCRV-II in grass carp. The findings support Dhcr7 as a promising research target in aquaculture genetics, but they remain a species-, pathogen-, and model-specific proof of concept rather than evidence that 7-dehydrocholesterol supplementation or DHCR7 inhibition would reproduce the phenotype.

• RHEB Neddylation and Tag-Based Evidence

  2026-10-13

  The reported study links the UBE2F–SAG neddylation axis to RHEB regulation, mTORC1 activity, liver steatosis and tumorigenesis. X-press Tag Peptide has a separate, product-defined role in recombinant protein purification and detection; the supplied evidence does not establish that it was used in the study or that it changes the biology described.

• EGTA, Calcium Chelation, and Cardiac Vagal Signaling

  2026-10-12

  The supplied study supports a pharmacological role for agatoxin-IVA-sensitive calcium channels in nicotine-evoked signaling in cardiac vagal neurons. It does not test EGTA, so its findings should not be interpreted as evidence that EGTA reproduces channel-blocker effects or provides neuroprotection.

• SUMO Protease (Ulp): Identity and Evidence Scope

  2026-10-12

  APExBIO’s product information identifies SKU K1103 as a recombinant Ulp1 protease intended for conceptual SUMO fusion-tag removal. No matched research paper or independent performance evidence was supplied, so claims about comparative efficiency, yield, purity, or target-specific suitability remain unverified.

• Minocycline HCl and MSC-EV Evidence Boundaries

  2026-10-11

  Minocycline hydrochloride has a documented pharmacological profile relevant to inflammation research, but the supplied evidence does not connect it to the reported extracellular-vesicle platform. Gong et al. support a preclinical scalability concept for EPSC-derived MSC extracellular vesicles, while important translational and mechanistic boundaries remain.

• Lowe Syndrome Gene Therapy Research Context

  2026-10-10

  A source-grounded overview of Lowe syndrome, OCRL biology, patient-derived trabecular meshwork models, and the reported comparison of gene augmentation with CRISPR-based correction. The evidence is preclinical and does not establish clinical efficacy or support PTC124 (Ataluren) as a Lowe syndrome treatment.

• CCR7–Notch1 Crosstalk in Mammary Cancer Stemness

  2026-10-09

  Boyle et al. identified functional crosstalk between CCR7 and Notch1 in primary MMTV-PyMT mammary cancer cells, linking chemokine signaling to stem-like tumor-cell behavior. The study supports a coordinated signaling model, while its murine and ex vivo design limits direct claims about human disease or therapeutic efficacy.

551 records 1/37 page Next 12345 下5页 Last page